Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) said the United States Patent and Trademark Office (USPTO) has granted allowance for the company’s patent application covering its short-duration novel psychedelic medications for the treatment of central nervous system (CNS) disorders.
Included in patent application number 17/387,864, titled ‘3-Pyrrolidine-Indole Derivatives as Serotonergic Psychedelic Agents for the Treatment of CNS Disorders’, are drug candidates that Mindset classifies as belonging to Family 2, which are novel analogues of psilocybin that exhibit a range of pharmacokinetic and pharmacodynamic improvements in pre-clinical studies.
Mindset said Family 2 is included in the company’s collaboration with the McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies, which was agreed in January this year.
READ: Mindset Pharma develops new patent-pending technology to deliver next generation psychedelic medicines intranasally
The aim of the collaboration is to further the development of Mindset's Families 2 and 4 of novel psychedelic compounds. The drug candidates under this platform show strong effect size in vitro and in vivo compared to psilocybin, are potentially shorter-acting, orally bioavailable and CNS penetrant, the company noted.
"Family 2 has a potentially superior in-clinic macrodose profile to psilocybin. This notice of allowance reaffirms the strength of Mindset's IP position and facilitates our ongoing development of Family 2, a highly differentiated asset in our mission to help patients with unmet needs via the discovery of optimized psychedelic medications," said James Lanthier, CEO of Mindset Pharma in a statement.
"Our Family 2 compounds have shown positive results thus far and we are looking forward to continuing our work with Otsuka to get closer to bringing Family 2 to clinical trials," he added.
To watch a video of Mindset's CEO and CSO discussing the above announcement in greater detail, click here
Contact the author at jon.hopkins@proactiveinvestors.com